Niagen Bioscience, Inc. (NAGE) 8-K Current Report: March 19, 2026
Filed: March 19, 2026
Health Care
Medicinal Chemicals & Botanical ProductsNiagen Bioscience, Inc. (NAGE) 8-K current report filed with SEC EDGAR on March 19, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 8.01: Other Events
Niagen Bioscience, Inc. 8-K Mar 19, 2026 Event Analysis
Item 8.01 · Other Events
- • Board increased share repurchase authorization to $20M from prior $10M, doubling buyback capacity to return capital to shareholders
- • $2.6M of stock repurchased through March 17, 2026, showing initial program uptake and market activity
- • Repurchases can occur via open market or private transactions, enhancing flexibility to optimize timing and pricing
- • Program duration remains 24 months from original approval, with Board retaining discretion to suspend or modify
- • Expanded buyback authorization signals confidence in stock valuation and commitment to shareholder returns
Other Niagen Bioscience, Inc. 8-K Filings
Get deeper insights on Niagen Bioscience, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.